Global Second-Generation Antihistamines Market Outlook, In-Depth Analysis & Forecast to 2031

TABLE OF CONTENTS

1 Study Coverage

• 1.1 Introduction to Second-Generation Antihistamines: Definition, Properties, and Key Attributes
• 1.2 Market Segmentation by Type
  • 1.2.1 Global Second-Generation Antihistamines Market Size by Type, 2020 VS 2024 VS 2031
  • 1.2.2 Cetirizine
  • 1.2.3 Levocetirizine
  • 1.2.4 Loratadine
  • 1.2.5 Desloratadine
  • 1.2.6 Fexofenadine
  • 1.2.7 Bilastine
  • 1.2.8 Rupatadine
• 1.3 Market Segmentation by Application
  • 1.3.1 Global Second-Generation Antihistamines Market Size by Application, 2020 VS 2024 VS 2031
  • 1.3.2 Allergic Rhinitis
  • 1.3.3 Urticaria
  • 1.3.4 Others
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Executive Summary

• 2.1 Global Second-Generation Antihistamines Revenue Estimates and Forecasts 2020-2031
• 2.2 Global Second-Generation Antihistamines Revenue by Region
  • 2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
  • 2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
  • 2.2.3 Global Revenue Market Share by Region (2020-2031)
• 2.3 Global Second-Generation Antihistamines Sales Estimates and Forecasts 2020-2031
• 2.4 Global Second-Generation Antihistamines Sales by Region
  • 2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
  • 2.4.2 Historical and Forecasted Sales by Region (2020-2031)
  • 2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
  • 2.4.4 Global Sales Market Share by Region (2020-2031)

3 Competition by Manufacturers

• 3.1 Global Second-Generation Antihistamines Sales by Manufacturers
  • 3.1.1 Global Sales Volume by Manufacturers (2020-2025)
  • 3.1.2 Global Top 5 and Top 10 Manufacturers'Market Share by Sales Volume (2024)
• 3.2 Global Second-Generation Antihistamines Manufacturer Revenue Rankings and Tiers
  • 3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
  • 3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
  • 3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
• 3.3 Manufacturer Profitability Profiles and Pricing Strategies
  • 3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
  • 3.3.2 Manufacturer-Level Price Trends (2020-2025)
• 3.4 Key Manufacturers Manufacturing Base and Headquarters
• 3.5 Main Product Type Market Size by Manufacturers
  • 3.5.1 Cetirizine Market Size by Manufacturers
  • 3.5.2 Levocetirizine Market Size by Manufacturers
  • 3.5.3 Loratadine Market Size by Manufacturers
  • 3.5.4 Desloratadine Market Size by Manufacturers
  • 3.5.5 Fexofenadine Market Size by Manufacturers
  • 3.5.6 Bilastine Market Size by Manufacturers
  • 3.5.7 Rupatadine Market Size by Manufacturers
• 3.6 Global Second-Generation Antihistamines Market Concentration and Dynamics
  • 3.6.1 Global Market Concentration (CR5 and HHI)
  • 3.6.2 Entrant/Exit Impact Analysis
  • 3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Global Product Segmentation Analysis

• 4.1 Global Second-Generation Antihistamines Sales Performance by Type
  • 4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
  • 4.1.2 Global Sales Market Share by Type (2020-2031)
• 4.2 Global Second-Generation Antihistamines Revenue Trends by Type
  • 4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
  • 4.2.2 Global Revenue Market Share by Type (2020-2031)
• 4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
• 4.4 Product Technology Differentiation
• 4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
  • 4.5.1 High-Growth Niches and Adoption Drivers
  • 4.5.2 Profitability Hotspots and Cost Drivers
  • 4.5.3 Substitution Threats

5 Global Downstream Application Analysis

• 5.1 Global Second-Generation Antihistamines Sales by Application
  • 5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
  • 5.1.2 Global Sales Market Share by Application (2020-2031)
  • 5.1.3 High-Growth Application Identification
  • 5.1.4 Emerging Application Case Studies
• 5.2 Global Second-Generation Antihistamines Revenue by Application
  • 5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
  • 5.2.2 Revenue Market Share by Application (2020-2031)
• 5.3 Global Pricing Dynamics by Application (2020-2031)
• 5.4 Downstream Customer Analysis
  • 5.4.1 Top Customers by Region
  • 5.4.2 Top Customers by Application

6 North America

• 6.1 North America Sales Volume and Revenue (2020-2031)
• 6.2 North America Key Manufacturers Sales Revenue in 2024
• 6.3 North America Second-Generation Antihistamines Sales and Revenue by Type (2020-2031)
• 6.4 North America Second-Generation Antihistamines Sales and Revenue by Application (2020-2031)
• 6.5 North America Growth Accelerators and Market Barriers
• 6.6 North America Second-Generation Antihistamines Market Size by Country
  • 6.6.1 North America Revenue by Country
  • 6.6.2 North America Sales Trends by Country
  • 6.6.3 US
  • 6.6.4 Canada
  • 6.6.5 Mexico

7 Europe

• 7.1 Europe Sales Volume and Revenue (2020-2031)
• 7.2 Europe Key Manufacturers Sales Revenue in 2024
• 7.3 Europe Second-Generation Antihistamines Sales and Revenue by Type (2020-2031)
• 7.4 Europe Second-Generation Antihistamines Sales and Revenue by Application (2020-2031)
• 7.5 Europe Growth Accelerators and Market Barriers
• 7.6 Europe Second-Generation Antihistamines Market Size by Country
  • 7.6.1 Europe Revenue by Country
  • 7.6.2 Europe Sales Trends by Country
  • 7.6.3 Germany
  • 7.6.4 France
  • 7.6.5 U.K.
  • 7.6.6 Italy
  • 7.6.7 Russia

8 Asia-Pacific

• 8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
• 8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
• 8.3 Asia-Pacific Second-Generation Antihistamines Sales and Revenue by Type (2020-2031)
• 8.4 Asia-Pacific Second-Generation Antihistamines Sales and Revenue by Application (2020-2031)
• 8.5 Asia-Pacific Second-Generation Antihistamines Market Size by Region
  • 8.5.1 Asia-Pacific Revenue by Region
  • 8.5.2 Asia-Pacific Sales Trends by Region
• 8.6 Asia-Pacific Growth Accelerators and Market Barriers
• 8.7 Southeast Asia
  • 8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
  • 8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
• 8.8 China
• 8.9 Japan
• 8.10 South Korea
• 8.11 China Taiwan
• 8.12 India

9 Central and South America

• 9.1 Central and South America Sales Volume and Revenue (2020-2031)
• 9.2 Central and South America Key Manufacturers Sales Revenue in 2024
• 9.3 Central and South America Second-Generation Antihistamines Sales and Revenue by Type (2020-2031)
• 9.4 Central and South America Second-Generation Antihistamines Sales and Revenue by Application (2020-2031)
• 9.5 Central and South America Investment Opportunities and Key Challenges
• 9.6 Central and South America Second-Generation Antihistamines Market Size by Country
  • 9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
  • 9.6.2 Brazil
  • 9.6.3 Argentina

10 Middle East and Africa

• 10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
• 10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
• 10.3 Middle East and Africa Second-Generation Antihistamines Sales and Revenue by Type (2020-2031)
• 10.4 Middle East and Africa Second-Generation Antihistamines Sales and Revenue by Application (2020-2031)
• 10.5 Middle East and Africa Investment Opportunities and Key Challenges
• 10.6 Middle East and Africa Second-Generation Antihistamines Market Size by Country
  • 10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
  • 10.6.2 GCC Countries
  • 10.6.3 Turkey
  • 10.6.4 Egypt
  • 10.6.5 South Africa

11 Corporate Profile

• 11.1 Sanofi
  • 11.1.1 Sanofi Corporation Information
  • 11.1.2 Sanofi Business Overview
  • 11.1.3 Sanofi Second-Generation Antihistamines Product Models, Descriptions and Specifications
  • 11.1.4 Sanofi Second-Generation Antihistamines Sales, Price, Revenue and Gross Margin (2020-2025)
  • 11.1.5 Sanofi Second-Generation Antihistamines Sales by Product in 2024
  • 11.1.6 Sanofi Second-Generation Antihistamines Sales by Application in 2024
  • 11.1.7 Sanofi Second-Generation Antihistamines Sales by Geographic Area in 2024
  • 11.1.8 Sanofi Second-Generation Antihistamines SWOT Analysis
  • 11.1.9 Sanofi Recent Developments
• 11.2 Bayer
  • 11.2.1 Bayer Corporation Information
  • 11.2.2 Bayer Business Overview
  • 11.2.3 Bayer Second-Generation Antihistamines Product Models, Descriptions and Specifications
  • 11.2.4 Bayer Second-Generation Antihistamines Sales, Price, Revenue and Gross Margin (2020-2025)
  • 11.2.5 Bayer Second-Generation Antihistamines Sales by Product in 2024
  • 11.2.6 Bayer Second-Generation Antihistamines Sales by Application in 2024
  • 11.2.7 Bayer Second-Generation Antihistamines Sales by Geographic Area in 2024
  • 11.2.8 Bayer Second-Generation Antihistamines SWOT Analysis
  • 11.2.9 Bayer Recent Developments
• 11.3 Novartis
  • 11.3.1 Novartis Corporation Information
  • 11.3.2 Novartis Business Overview
  • 11.3.3 Novartis Second-Generation Antihistamines Product Models, Descriptions and Specifications
  • 11.3.4 Novartis Second-Generation Antihistamines Sales, Price, Revenue and Gross Margin (2020-2025)
  • 11.3.5 Novartis Second-Generation Antihistamines Sales by Product in 2024
  • 11.3.6 Novartis Second-Generation Antihistamines Sales by Application in 2024
  • 11.3.7 Novartis Second-Generation Antihistamines Sales by Geographic Area in 2024
  • 11.3.8 Novartis Second-Generation Antihistamines SWOT Analysis
  • 11.3.9 Novartis Recent Developments
• 11.4 Johnson & Johnson
  • 11.4.1 Johnson & Johnson Corporation Information
  • 11.4.2 Johnson & Johnson Business Overview
  • 11.4.3 Johnson & Johnson Second-Generation Antihistamines Product Models, Descriptions and Specifications
  • 11.4.4 Johnson & Johnson Second-Generation Antihistamines Sales, Price, Revenue and Gross Margin (2020-2025)
  • 11.4.5 Johnson & Johnson Second-Generation Antihistamines Sales by Product in 2024
  • 11.4.6 Johnson & Johnson Second-Generation Antihistamines Sales by Application in 2024
  • 11.4.7 Johnson & Johnson Second-Generation Antihistamines Sales by Geographic Area in 2024
  • 11.4.8 Johnson & Johnson Second-Generation Antihistamines SWOT Analysis
  • 11.4.9 Johnson & Johnson Recent Developments
• 11.5 UCB Pharma
  • 11.5.1 UCB Pharma Corporation Information
  • 11.5.2 UCB Pharma Business Overview
  • 11.5.3 UCB Pharma Second-Generation Antihistamines Product Models, Descriptions and Specifications
  • 11.5.4 UCB Pharma Second-Generation Antihistamines Sales, Price, Revenue and Gross Margin (2020-2025)
  • 11.5.5 UCB Pharma Second-Generation Antihistamines Sales by Product in 2024
  • 11.5.6 UCB Pharma Second-Generation Antihistamines Sales by Application in 2024
  • 11.5.7 UCB Pharma Second-Generation Antihistamines Sales by Geographic Area in 2024
  • 11.5.8 UCB Pharma Second-Generation Antihistamines SWOT Analysis
  • 11.5.9 UCB Pharma Recent Developments
• 11.6 Faes Farma
  • 11.6.1 Faes Farma Corporation Information
  • 11.6.2 Faes Farma Business Overview
  • 11.6.3 Faes Farma Second-Generation Antihistamines Product Models, Descriptions and Specifications
  • 11.6.4 Faes Farma Second-Generation Antihistamines Sales, Price, Revenue and Gross Margin (2020-2025)
  • 11.6.5 Faes Farma Recent Developments
• 11.7 Teva
  • 11.7.1 Teva Corporation Information
  • 11.7.2 Teva Business Overview
  • 11.7.3 Teva Second-Generation Antihistamines Product Models, Descriptions and Specifications
  • 11.7.4 Teva Second-Generation Antihistamines Sales, Price, Revenue and Gross Margin (2020-2025)
  • 11.7.5 Teva Recent Developments
• 11.8 Pfizer
  • 11.8.1 Pfizer Corporation Information
  • 11.8.2 Pfizer Business Overview
  • 11.8.3 Pfizer Second-Generation Antihistamines Product Models, Descriptions and Specifications
  • 11.8.4 Pfizer Second-Generation Antihistamines Sales, Price, Revenue and Gross Margin (2020-2025)
  • 11.8.5 Pfizer Recent Developments
• 11.9 Chia Tai Tianqing
  • 11.9.1 Chia Tai Tianqing Corporation Information
  • 11.9.2 Chia Tai Tianqing Business Overview
  • 11.9.3 Chia Tai Tianqing Second-Generation Antihistamines Product Models, Descriptions and Specifications
  • 11.9.4 Chia Tai Tianqing Second-Generation Antihistamines Sales, Price, Revenue and Gross Margin (2020-2025)
  • 11.9.5 Chia Tai Tianqing Recent Developments
• 11.10 Yangtze River Pharma
  • 11.10.1 Yangtze River Pharma Corporation Information
  • 11.10.2 Yangtze River Pharma Business Overview
  • 11.10.3 Yangtze River Pharma Second-Generation Antihistamines Product Models, Descriptions and Specifications
  • 11.10.4 Yangtze River Pharma Second-Generation Antihistamines Sales, Price, Revenue and Gross Margin (2020-2025)
  • 11.10.5 Yangtze River Pharma Recent Developments
• 11.11 Hainan Huahai Pharma
  • 11.11.1 Hainan Huahai Pharma Corporation Information
  • 11.11.2 Hainan Huahai Pharma Business Overview
  • 11.11.3 Hainan Huahai Pharma Second-Generation Antihistamines Product Models, Descriptions and Specifications
  • 11.11.4 Hainan Huahai Pharma Second-Generation Antihistamines Sales, Price, Revenue and Gross Margin (2020-2025)
  • 11.11.5 Hainan Huahai Pharma Recent Developments
• 11.12 Hengrui Medicine
  • 11.12.1 Hengrui Medicine Corporation Information
  • 11.12.2 Hengrui Medicine Business Overview
  • 11.12.3 Hengrui Medicine Second-Generation Antihistamines Product Models, Descriptions and Specifications
  • 11.12.4 Hengrui Medicine Second-Generation Antihistamines Sales, Price, Revenue and Gross Margin (2020-2025)
  • 11.12.5 Hengrui Medicine Recent Developments
• 11.13 CSPC Pharmaceutical
  • 11.13.1 CSPC Pharmaceutical Corporation Information
  • 11.13.2 CSPC Pharmaceutical Business Overview
  • 11.13.3 CSPC Pharmaceutical Second-Generation Antihistamines Product Models, Descriptions and Specifications
  • 11.13.4 CSPC Pharmaceutical Second-Generation Antihistamines Sales, Price, Revenue and Gross Margin (2020-2025)
  • 11.13.5 CSPC Pharmaceutical Recent Developments
• 11.14 Qilu Pharmaceutical
  • 11.14.1 Qilu Pharmaceutical Corporation Information
  • 11.14.2 Qilu Pharmaceutical Business Overview
  • 11.14.3 Qilu Pharmaceutical Second-Generation Antihistamines Product Models, Descriptions and Specifications
  • 11.14.4 Qilu Pharmaceutical Second-Generation Antihistamines Sales, Price, Revenue and Gross Margin (2020-2025)
  • 11.14.5 Qilu Pharmaceutical Recent Developments
• 11.15 Guangzhou Baiyunshan
  • 11.15.1 Guangzhou Baiyunshan Corporation Information
  • 11.15.2 Guangzhou Baiyunshan Business Overview
  • 11.15.3 Guangzhou Baiyunshan Second-Generation Antihistamines Product Models, Descriptions and Specifications
  • 11.15.4 Guangzhou Baiyunshan Second-Generation Antihistamines Sales, Price, Revenue and Gross Margin (2020-2025)
  • 11.15.5 Guangzhou Baiyunshan Recent Developments
• 11.16 Taiji Group
  • 11.16.1 Taiji Group Corporation Information
  • 11.16.2 Taiji Group Business Overview
  • 11.16.3 Taiji Group Second-Generation Antihistamines Product Models, Descriptions and Specifications
  • 11.16.4 Taiji Group Second-Generation Antihistamines Sales, Price, Revenue and Gross Margin (2020-2025)
  • 11.16.5 Taiji Group Recent Developments
• 11.17 Proya Pharma
  • 11.17.1 Proya Pharma Corporation Information
  • 11.17.2 Proya Pharma Business Overview
  • 11.17.3 Proya Pharma Second-Generation Antihistamines Product Models, Descriptions and Specifications
  • 11.17.4 Proya Pharma Second-Generation Antihistamines Sales, Price, Revenue and Gross Margin (2020-2025)
  • 11.17.5 Proya Pharma Recent Developments

12 Value Chain and Supply-Chain Analysis

• 12.1 Second-Generation Antihistamines Industry Chain
• 12.2 Second-Generation Antihistamines Upstream Materials Analysis
  • 12.2.1 Raw Materials
  • 12.2.2 Key Suppliers Market Share & Risk Assessment
• 12.3 Second-Generation Antihistamines Integrated Production Analysis
  • 12.3.1 Manufacturing Footprint Analysis
  • 12.3.2 Regional Production Market Share (2020-2031)
  • 12.3.3 Regulatory and Trade Policy Impact on Production
  • 12.3.4 Production Technology Overview
  • 12.3.5 Regional Cost Drivers
• 12.4 Second-Generation Antihistamines Sales Channels and Distribution Networks
  • 12.4.1 Sales Channels
  • 12.4.2 Distributors

13 Second-Generation Antihistamines Market Dynamics

• 13.1 Industry Trends and Evolution
• 13.2 Market Growth Drivers and Emerging Opportunities
• 13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Second-Generation Antihistamines Study

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 15.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Author Details

List of Tables

Table 1. Global Second-Generation Antihistamines Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Second-Generation Antihistamines Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Second-Generation Antihistamines Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Second-Generation Antihistamines Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Second-Generation Antihistamines Revenue by Region (2026-2031) & (US$ Million)

Table 6. Global Second-Generation Antihistamines Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)

Table 7. Global Second-Generation Antihistamines Sales by Region (2020-2025) & (K Units)

Table 8. Global Second-Generation Antihistamines Sales by Region (2026-2031) & (K Units)

Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 10. Global Second-Generation Antihistamines Sales by Manufacturers (2020-2025) & (K Units)

Table 11. Global Second-Generation Antihistamines Sales Share by Manufacturers (2020-2025)

Table 12. Global Second-Generation Antihistamines Revenue by Manufacturers (2020-2025) & (US$ Million)

Table 13. Global Second-Generation Antihistamines Revenue Market Share by Manufacturers (2020-2025)

Table 14. Global Key Manufacturers'Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 15. Global Second-Generation Antihistamines by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Second-Generation Antihistamines as of 2024)

Table 16. Global Second-Generation Antihistamines Average Gross Margin (%) by Manufacturer (2020 VS 2024)

Table 17. Global Second-Generation Antihistamines Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)

Table 18. Key Manufacturers Second-Generation Antihistamines Manufacturing Base and Headquarters

Table 19. Global Second-Generation Antihistamines Market Concentration Ratio (CR5 and HHI)

Table 20. Key Market Entrant/Exit (2020-2024) - Drivers & Impact Analysis

Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 22. Global Second-Generation Antihistamines Sales by Type (2020-2025) & (K Units)

Table 23. Global Second-Generation Antihistamines Sales by Type (2026-2031) & (K Units)

Table 24. Global Second-Generation Antihistamines Revenue by Type (2020-2025) & (US$ Million)

Table 25. Global Second-Generation Antihistamines Revenue by Type (2026-2031) & (US$ Million)

Table 26. Global Second-Generation Antihistamines ASP by Type (2020-2031) & (US$/Unit)

Table 27. Technical Specifications by Key Product Type

Table 28. Global Second-Generation Antihistamines Sales by Application (2020-2025) & (K Units)

Table 29. Global Second-Generation Antihistamines Sales by Application (2026-2031) & (K Units)

Table 30. Second-Generation Antihistamines High-Growth Sectors Demand CAGR (2024-2031)

Table 31. Global Second-Generation Antihistamines Revenue by Application (2020-2025) & (US$ Million)

Table 32. Global Second-Generation Antihistamines Revenue by Application (2026-2031) & (US$ Million)

Table 33. Global Second-Generation Antihistamines ASP by Application (2020-2031) & (US$/Unit)

Table 34. Top Customers by Region

Table 35. Top Customers by Application

Table 36. North America Second-Generation Antihistamines Growth Accelerators and Market Barriers

Table 37. North America Second-Generation Antihistamines Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 38. North America Second-Generation Antihistamines Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 39. Europe Second-Generation Antihistamines Growth Accelerators and Market Barriers

Table 40. Europe Second-Generation Antihistamines Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Europe Second-Generation Antihistamines Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 42. Asia-Pacific Second-Generation Antihistamines Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 43. Asia-Pacific Second-Generation Antihistamines Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 44. Asia-Pacific Second-Generation Antihistamines Growth Accelerators and Market Barriers

Table 45. Southeast Asia Second-Generation Antihistamines Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Central and South America Second-Generation Antihistamines Investment Opportunities and Key Challenges

Table 47. Central and South America Second-Generation Antihistamines Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 48. Middle East and Africa Second-Generation Antihistamines Investment Opportunities and Key Challenges

Table 49. Middle East and Africa Second-Generation Antihistamines Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 50. Sanofi Corporation Information

Table 51. Sanofi Description and Major Businesses

Table 52. Sanofi Product Models, Descriptions and Specifications

Table 53. Sanofi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 54. Sanofi Sales Value Proportion by Product in 2024

Table 55. Sanofi Sales Value Proportion by Application in 2024

Table 56. Sanofi Sales Value Proportion by Geographic Area in 2024

Table 57. Sanofi Second-Generation Antihistamines SWOT Analysis

Table 58. Sanofi Recent Developments

Table 59. Bayer Corporation Information

Table 60. Bayer Description and Major Businesses

Table 61. Bayer Product Models, Descriptions and Specifications

Table 62. Bayer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 63. Bayer Sales Value Proportion by Product in 2024

Table 64. Bayer Sales Value Proportion by Application in 2024

Table 65. Bayer Sales Value Proportion by Geographic Area in 2024

Table 66. Bayer Second-Generation Antihistamines SWOT Analysis

Table 67. Bayer Recent Developments

Table 68. Novartis Corporation Information

Table 69. Novartis Description and Major Businesses

Table 70. Novartis Product Models, Descriptions and Specifications

Table 71. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 72. Novartis Sales Value Proportion by Product in 2024

Table 73. Novartis Sales Value Proportion by Application in 2024

Table 74. Novartis Sales Value Proportion by Geographic Area in 2024

Table 75. Novartis Second-Generation Antihistamines SWOT Analysis

Table 76. Novartis Recent Developments

Table 77. Johnson & Johnson Corporation Information

Table 78. Johnson & Johnson Description and Major Businesses

Table 79. Johnson & Johnson Product Models, Descriptions and Specifications

Table 80. Johnson & Johnson Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 81. Johnson & Johnson Sales Value Proportion by Product in 2024

Table 82. Johnson & Johnson Sales Value Proportion by Application in 2024

Table 83. Johnson & Johnson Sales Value Proportion by Geographic Area in 2024

Table 84. Johnson & Johnson Second-Generation Antihistamines SWOT Analysis

Table 85. Johnson & Johnson Recent Developments

Table 86. UCB Pharma Corporation Information

Table 87. UCB Pharma Description and Major Businesses

Table 88. UCB Pharma Product Models, Descriptions and Specifications

Table 89. UCB Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 90. UCB Pharma Sales Value Proportion by Product in 2024

Table 91. UCB Pharma Sales Value Proportion by Application in 2024

Table 92. UCB Pharma Sales Value Proportion by Geographic Area in 2024

Table 93. UCB Pharma Second-Generation Antihistamines SWOT Analysis

Table 94. UCB Pharma Recent Developments

Table 95. Faes Farma Corporation Information

Table 96. Faes Farma Description and Major Businesses

Table 97. Faes Farma Product Models, Descriptions and Specifications

Table 98. Faes Farma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 99. Faes Farma Recent Developments

Table 100. Teva Corporation Information

Table 101. Teva Description and Major Businesses

Table 102. Teva Product Models, Descriptions and Specifications

Table 103. Teva Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 104. Teva Recent Developments

Table 105. Pfizer Corporation Information

Table 106. Pfizer Description and Major Businesses

Table 107. Pfizer Product Models, Descriptions and Specifications

Table 108. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 109. Pfizer Recent Developments

Table 110. Chia Tai Tianqing Corporation Information

Table 111. Chia Tai Tianqing Description and Major Businesses

Table 112. Chia Tai Tianqing Product Models, Descriptions and Specifications

Table 113. Chia Tai Tianqing Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 114. Chia Tai Tianqing Recent Developments

Table 115. Yangtze River Pharma Corporation Information

Table 116. Yangtze River Pharma Description and Major Businesses

Table 117. Yangtze River Pharma Product Models, Descriptions and Specifications

Table 118. Yangtze River Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 119. Yangtze River Pharma Recent Developments

Table 120. Hainan Huahai Pharma Corporation Information

Table 121. Hainan Huahai Pharma Description and Major Businesses

Table 122. Hainan Huahai Pharma Product Models, Descriptions and Specifications

Table 123. Hainan Huahai Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 124. Hainan Huahai Pharma Recent Developments

Table 125. Hengrui Medicine Corporation Information

Table 126. Hengrui Medicine Description and Major Businesses

Table 127. Hengrui Medicine Product Models, Descriptions and Specifications

Table 128. Hengrui Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 129. Hengrui Medicine Recent Developments

Table 130. CSPC Pharmaceutical Corporation Information

Table 131. CSPC Pharmaceutical Description and Major Businesses

Table 132. CSPC Pharmaceutical Product Models, Descriptions and Specifications

Table 133. CSPC Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 134. CSPC Pharmaceutical Recent Developments

Table 135. Qilu Pharmaceutical Corporation Information

Table 136. Qilu Pharmaceutical Description and Major Businesses

Table 137. Qilu Pharmaceutical Product Models, Descriptions and Specifications

Table 138. Qilu Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 139. Qilu Pharmaceutical Recent Developments

Table 140. Guangzhou Baiyunshan Corporation Information

Table 141. Guangzhou Baiyunshan Description and Major Businesses

Table 142. Guangzhou Baiyunshan Product Models, Descriptions and Specifications

Table 143. Guangzhou Baiyunshan Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 144. Guangzhou Baiyunshan Recent Developments

Table 145. Taiji Group Corporation Information

Table 146. Taiji Group Description and Major Businesses

Table 147. Taiji Group Product Models, Descriptions and Specifications

Table 148. Taiji Group Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 149. Taiji Group Recent Developments

Table 150. Proya Pharma Corporation Information

Table 151. Proya Pharma Description and Major Businesses

Table 152. Proya Pharma Product Models, Descriptions and Specifications

Table 153. Proya Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 154. Proya Pharma Recent Developments

Table 155. Key Raw Materials Distribution

Table 156. Raw Materials Key Suppliers

Table 157. Critical Raw Material Supplier Concentration (2024) & Risk Index

Table 158. Milestones in Production Technology Evolution

Table 159. Distributors List

Table 160. Market Trends and Market Evolution

Table 161. Market Drivers and Opportunities

Table 162. Market Challenges, Risks, and Restraints

Table 163. Research Programs/Design for This Report

Table 164. Key Data Information from Secondary Sources

Table 165. Key Data Information from Primary Sources

List of Figures

Figure 1. Second-Generation Antihistamines Product Picture

Figure 2. Global Second-Generation Antihistamines Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Cetirizine Product Picture

Figure 4. Levocetirizine Product Picture

Figure 5. Loratadine Product Picture

Figure 6. Desloratadine Product Picture

Figure 7. Fexofenadine Product Picture

Figure 8. Bilastine Product Picture

Figure 9. Rupatadine Product Picture

Figure 10. Global Second-Generation Antihistamines Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 11. Allergic Rhinitis

Figure 12. Urticaria

Figure 13. Others

Figure 14. Second-Generation Antihistamines Report Years Considered

Figure 15. Global Second-Generation Antihistamines Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Second-Generation Antihistamines Revenue (2020-2031) & (US$ Million)

Figure 17. Global Second-Generation Antihistamines Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 18. Global Second-Generation Antihistamines Revenue Market Share by Region (2020-2031)

Figure 19. Global Second-Generation Antihistamines Sales (2020-2031) & (K Units)

Figure 20. Global Second-Generation Antihistamines Sales (CAGR) by Region (2020-2031) (K Units)

Figure 21. Global Second-Generation Antihistamines Sales Market Share by Region (2020-2031)

Figure 22. Top 5 and Top 10 Manufacturers Second-Generation Antihistamines Sales Volume Market Share in 2024

Figure 23. Global Second-Generation Antihistamines Revenue Market Share Ranking (2024)

Figure 24. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 25. Cetirizine Revenue Market Share by Manufacturer in 2024

Figure 26. Levocetirizine Revenue Market Share by Manufacturer in 2024

Figure 27. Loratadine Revenue Market Share by Manufacturer in 2024

Figure 28. Desloratadine Revenue Market Share by Manufacturer in 2024

Figure 29. Fexofenadine Revenue Market Share by Manufacturer in 2024

Figure 30. Bilastine Revenue Market Share by Manufacturer in 2024

Figure 31. Rupatadine Revenue Market Share by Manufacturer in 2024

Figure 32. Global Second-Generation Antihistamines Sales Market Share by Type (2020-2031)

Figure 33. Global Second-Generation Antihistamines Revenue Market Share by Type (2020-2031)

Figure 34. Global Second-Generation Antihistamines Sales Market Share by Application (2020-2031)

Figure 35. Global Second-Generation Antihistamines Revenue Market Share by Application (2020-2031)

Figure 36. North America Second-Generation Antihistamines Sales YoY (2020-2031) & (K Units)

Figure 37. North America Second-Generation Antihistamines Revenue YoY (2020-2031) & (US$ Million)

Figure 38. North America Top 5 Manufacturers Second-Generation Antihistamines Sales Revenue (US$ Million) in 2024

Figure 39. North America Second-Generation Antihistamines Sales Volume (K Units) by Type (2020- 2031)

Figure 40. North America Second-Generation Antihistamines Sales Revenue (US$ Million) by Type (2020 - 2031)

Figure 41. North America Second-Generation Antihistamines Sales Volume (K Units) by Application (2020-2031)

Figure 42. North America Second-Generation Antihistamines Sales Revenue (US$ Million) by Application (2020-2031)

Figure 43. US Second-Generation Antihistamines Revenue (2020-2031) & (US$ Million)

Figure 44. Canada Second-Generation Antihistamines Revenue (2020-2031) & (US$ Million)

Figure 45. Mexico Second-Generation Antihistamines Revenue (2020-2031) & (US$ Million)

Figure 46. Europe Second-Generation Antihistamines Sales YoY (2020-2031) & (K Units)

Figure 47. Europe Second-Generation Antihistamines Revenue YoY (2020-2031) & (US$ Million)

Figure 48. Europe Top 5 Manufacturers Second-Generation Antihistamines Sales Revenue (US$ Million) in 2024

Figure 49. Europe Second-Generation Antihistamines Sales Volume (K Units) by Type (2020-2031)

Figure 50. Europe Second-Generation Antihistamines Sales Revenue (US$ Million) by Type (2020-2031)

Figure 51. Europe Second-Generation Antihistamines Sales Volume (K Units) by Application (2020-2031)

Figure 52. Europe Second-Generation Antihistamines Sales Revenue (US$ Million) by Application (2020-2031)

Figure 53. Germany Second-Generation Antihistamines Revenue (2020-2031) & (US$ Million)

Figure 54. France Second-Generation Antihistamines Revenue (2020-2031) & (US$ Million)

Figure 55. U.K. Second-Generation Antihistamines Revenue (2020-2031) & (US$ Million)

Figure 56. Italy Second-Generation Antihistamines Revenue (2020-2031) & (US$ Million)

Figure 57. Russia Second-Generation Antihistamines Revenue (2020-2031) & (US$ Million)

Figure 58. Asia-Pacific Second-Generation Antihistamines Sales YoY (2020-2031) & (K Units)

Figure 59. Asia-Pacific Second-Generation Antihistamines Revenue YoY (2020-2031) & (US$ Million)

Figure 60. Asia-Pacific Top 8 Manufacturers Second-Generation Antihistamines Sales Revenue (US$ Million) in 2024

Figure 61. Asia-Pacific Second-Generation Antihistamines Sales Volume (K Units) by Type (2020- 2031)

Figure 62. Asia-Pacific Second-Generation Antihistamines Sales Revenue (US$ Million) by Type (2020- 2031)

Figure 63. Asia-Pacific Second-Generation Antihistamines Sales Volume (K Units) by Application (2020-2031)

Figure 64. Asia-Pacific Second-Generation Antihistamines Sales Revenue (US$ Million) by Application (2020-2031)

Figure 65. Indonesia Second-Generation Antihistamines Revenue (2020-2031) & (US$ Million)

Figure 66. Japan Second-Generation Antihistamines Revenue (2020-2031) & (US$ Million)

Figure 67. South Korea Second-Generation Antihistamines Revenue (2020-2031) & (US$ Million)

Figure 68. China Taiwan Second-Generation Antihistamines Revenue (2020-2031) & (US$ Million)

Figure 69. India Second-Generation Antihistamines Revenue (2020-2031) & (US$ Million)

Figure 70. Central and South America Second-Generation Antihistamines Sales YoY (2020-2031) & (K Units)

Figure 71. Central and South America Second-Generation Antihistamines Revenue YoY (2020-2031) & (US$ Million)

Figure 72. Central and South America Top 5 Manufacturers Second-Generation Antihistamines Sales Revenue (US$ Million) in 2024

Figure 73. Central and South America Second-Generation Antihistamines Sales Volume (K Units) by Type (2021-2031)

Figure 74. Central and South America Second-Generation Antihistamines Sales Revenue (US$ Million) by Type (2020-2031)

Figure 75. Central and South America Second-Generation Antihistamines Sales Volume (K Units) by Application (2020-2031)

Figure 76. Central and South America Second-Generation Antihistamines Sales Revenue (US$ Million) by Application (2020-2031)

Figure 77. Brazil Second-Generation Antihistamines Revenue (2020-2025) & (US$ Million)

Figure 78. Argentina Second-Generation Antihistamines Revenue (2020-2025) & (US$ Million)

Figure 79. Middle East, and Africa Second-Generation Antihistamines Sales YoY (2020-2031) & (K Units)

Figure 80. Middle East and Africa Second-Generation Antihistamines Revenue YoY (2020-2031) & (US$ Million)

Figure 81. Middle East and Africa Top 5 Manufacturers Second-Generation Antihistamines Sales Revenue (US$ Million) in 2024

Figure 82. Middle East and Africa Second-Generation Antihistamines Sales Volume (K Units) by Type (2021-2031)

Figure 83. South America Second-Generation Antihistamines Sales Revenue (US$ Million) by Type (2020-2031)

Figure 84. Middle East and Africa Second-Generation Antihistamines Sales Volume (K Units) by Application (2020-2031)

Figure 85. Middle East and Africa Second-Generation Antihistamines Sales Revenue (US$ Million) by Application (2020-2031)

Figure 86. GCC Countries Second-Generation Antihistamines Revenue (2020-2025) & (US$ Million)

Figure 87. Turkey Second-Generation Antihistamines Revenue (2020-2025) & (US$ Million)

Figure 88. Egypt Second-Generation Antihistamines Revenue (2020-2025) & (US$ Million)

Figure 89. South Africa Second-Generation Antihistamines Revenue (2020-2025) & (US$ Million)

Figure 90. Second-Generation Antihistamines Industry Chain Mapping

Figure 91. Regional Second-Generation Antihistamines Manufacturing Base Distribution (%)

Figure 92. Global Second-Generation Antihistamines Production Market Share by Region (2020-2031)

Figure 93. Second-Generation Antihistamines Production Process

Figure 94. Regional Second-Generation Antihistamines Production Cost Structure

Figure 95. Channels of Distribution (Direct Vs Distribution)

Figure 96. Bottom-up and Top-down Approaches for This Report

Figure 97. Data Triangulation

Figure 98. Key Executives Interviewed